Analysts Set Hims & Hers Health, Inc. (NYSE:HIMS) Price Target at $21.43

Hims & Hers Health, Inc. (NYSE:HIMS) has received a consensus rating of “Hold” from the seventeen research firms that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and eight have issued a buy rating on the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $22.80.

A number of equities analysts have commented on HIMS shares. Morgan Stanley began coverage on Hims & Hers Health in a research note on Tuesday. They set an “overweight” rating and a $42.00 price objective on the stock. Bank of America cut Hims & Hers Health from a “buy” rating to an “underperform” rating and decreased their price target for the stock from $32.00 to $18.00 in a research report on Thursday, November 14th. Piper Sandler reiterated a “neutral” rating and set a $21.00 price objective (up from $18.00) on shares of Hims & Hers Health in a research note on Tuesday, November 5th. Deutsche Bank Aktiengesellschaft raised their target price on shares of Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a report on Wednesday, November 6th. Finally, TD Cowen reaffirmed a “buy” rating and set a $28.00 price target on shares of Hims & Hers Health in a report on Wednesday, November 20th.

Insider Activity at Hims & Hers Health

In other Hims & Hers Health news, CFO Oluyemi Okupe sold 269,739 shares of the company’s stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $20.31, for a total value of $5,478,399.09. Following the completion of the transaction, the chief financial officer now directly owns 145,763 shares in the company, valued at approximately $2,960,446.53. This represents a 64.92 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Michael Chi sold 2,054 shares of Hims & Hers Health stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $33.56, for a total transaction of $68,932.24. Following the transaction, the insider now owns 184,947 shares in the company, valued at approximately $6,206,821.32. This trade represents a 1.10 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 1,085,157 shares of company stock valued at $26,765,193 in the last 90 days. 17.71% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Hims & Hers Health

Institutional investors have recently made changes to their positions in the stock. Nisa Investment Advisors LLC boosted its position in Hims & Hers Health by 679.2% during the second quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock valued at $37,000 after acquiring an additional 1,603 shares during the last quarter. Quest Partners LLC boosted its position in shares of Hims & Hers Health by 5,944.1% during the 2nd quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock valued at $72,000 after purchasing an additional 3,507 shares in the last quarter. CWM LLC grew its stake in Hims & Hers Health by 21.4% during the third quarter. CWM LLC now owns 5,982 shares of the company’s stock worth $110,000 after purchasing an additional 1,054 shares during the period. Van ECK Associates Corp acquired a new stake in Hims & Hers Health during the second quarter worth approximately $111,000. Finally, Quarry LP increased its holdings in Hims & Hers Health by 91.0% in the third quarter. Quarry LP now owns 6,113 shares of the company’s stock worth $113,000 after purchasing an additional 2,913 shares in the last quarter. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Price Performance

Shares of NYSE HIMS opened at $26.20 on Monday. The firm has a market cap of $5.72 billion, a price-to-earnings ratio of 59.55 and a beta of 1.25. The stock’s fifty day moving average price is $25.78 and its two-hundred day moving average price is $21.27. Hims & Hers Health has a one year low of $8.09 and a one year high of $35.02.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.06 by $0.26. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The company had revenue of $401.56 million during the quarter, compared to analysts’ expectations of $382.20 million. During the same quarter in the previous year, the business posted ($0.04) earnings per share. Hims & Hers Health’s quarterly revenue was up 77.1% on a year-over-year basis. On average, equities analysts anticipate that Hims & Hers Health will post 0.29 earnings per share for the current fiscal year.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.